World's First: BonYao Bio's BCMA UCAR-T Successfully Treats Neuromyelitis Optica Spectrum Disorder

October 11, 2025, focusing on gene and cell therapy, BRL Medicine Inc.(hereinafter referred to as "BRL Medicine")Life"Thing")It was announced that a major breakthrough has been achieved in the clinical research jointly conducted by BRL Medicine, which provided core cell therapy products and technical support, along with the teams led by Professor Liu Mingyao and Du Bing from East China Normal University, Professor Wu Wencan's team from the Eye Hospital of Wenzhou Medical University, and Oujang Laboratory.World's First Use of Targeted BCMA Allogeneic Universal CAR-T Cells（BCMA UCAR-T）Treatment of Neuromyelitis Optica Spectrum Disorders（NMOSD）The patient has successfully completed the treatment and was discharged yesterday, October 10.This achievement not only means that BRL Medicine is once again at the international forefront in the research and clinical transformation of universal CAR-T cell drugs, but also marks a significant advancement in BRL Medicine's technological layout in the field of autoimmune disease treatment, bringing new hope to patients with refractory neurological autoimmune diseases worldwide.

Picture of Minimally Invasive Ophthalmology and Rhinology Specialty Team with Patients and Their Families (Third and Fourth from the Left)

Neuromyelitis Optica Spectrum Disorders（NMOSD）It is an autoimmune-mediated demyelinating disease of the central nervous system, with clinical manifestations primarily including sudden vision loss, eye movement pain, limb weakness/numbness, and even paralysis due to severe optic neuritis and longitudinally extensive transverse myelitis. This disease is highly prone to relapse, leading to high disability and blindness. Statistics show that over 90% of untreated NMOSD patients will experience a relapse, resulting in irreversible visual impairment and ultimately irreversible optic atrophy. Although various drugs have been approved for NMOSD treatment, many patients still show suboptimal responses.

BRL Medicine Relies on the World's First TyUCell^®Core technology of universal cell platform successfully developed an allogeneic UCAR-T cell drug targeting BCMA. This therapy aims to achieve immune reconstitution and deep immune tolerance induction by precisely eliminating plasma cells that produce pathogenic antibodies in the body.

New Product Trial

6-well/24-well/100ml Culture Flask

Application for New Product Trial

Event Time: September-October

The first patient to receive this treatment had long been suffering from NMOSD, unable to see objects clearly in front of them and enduring both physical pain and psychological stress, leading to extreme physical and mental exhaustion. After learning about the study from various sources, they participated in this clinical trial. Following the infusion treatment with BRL Medicine's innovative BCMA UCAR-T, the patient did not experience significant toxic side effects, with only a transient low-grade fever recorded.（≤38℃）Currently, the patient has discontinued all immunosuppressants. The initial efficacy evaluation shows that the target cells have been successfully eliminated, and the patient was discharged smoothly after the observation period. The patient and their family highly recognized the treatment outcome at the time of discharge and expressed gratitude to the research team.Notably, this is also the world's first successful case of BCMA UCAR-T cell therapy for neuromyelitis optica spectrum disorder (NMOSD).

Professor Mingyao Liu, founder of BRL Medicine, stated: "The success of this clinical study not only verifies the feasibility and safety of BRL Medicine's BCMA UCAR-T technology but also provides a new treatment approach and drug solution for NMOSD and other autoimmune diseases. BRL Medicine will continue to advance the systematic follow-up and subsequent clinical research of this project, accelerating the industrialization of allogeneic universal UCAR-T and other innovative therapies to benefit a wide range of patients."

Exciting Live Broadcast Preview

Press and hold to scan the QR code and participate immediately ↓

Recommendation 1

October 21st, 19:00-20:30

Focus on Flow Cytometry: Interpretation of Innovative Drug Development Strategies Across the Entire Cycle

Recommendation 2

October 24, 14:00-16:30

Offline Salon | Exosome "Drug" Era: IND Application and Key Technical Pathways Seminar

DianDian "Share”、“Like" and "In Progress", charge me up a bit~"